ArticleDrugs in context2021
The race to a COVID-19 vaccine: opportunities and challenges in development and distribution.
Article in Drugs in context, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Inequality in the distribution of Covid-19 vaccine: a systematic review.International journal for equity in health · 2022Pooled it
- Multi-perspectives systematic review on the applications of sentiment analysis for vaccine hesitancy.Computers in biology and medicine · 2021Pooled it
- Impact of Patient Portal Messaging Reminders with Self-Scheduling Option on Influenza Vaccination Rates: a Prospective, Randomized Trial.Journal of general internal medicine · 2022Trial
- Light-assisted drying enables vaccine stabilization and supports cold-chain-independent distribution.Scientific reports · 2026Article
- Tracking COVID-19 vaccination barriers over time: a census-tract-level barrier index approach.Epidemiology and infection · 2026Article
- Editorial: Pandemic preparedness in vaccine safety and regulation.Frontiers in drug safety and regulation · 2026Article
- Behind political affiliation: How moral values, identity politics, and party loyalty have affected COVID-19 vaccination.PloS one · 2025Article
- Competition Law and Ethics of Innovation as Catalysts for Fairness: Reimagining the EU's COVID-19 Vaccine Strategy.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2025Article
- Article
- Coronavirus Disease 2019 (COVID-19) Vaccination Status Prior to Delivery and Administration Among Hospitalized Obstetric Patients.North Carolina medical journal · 2024Article
- COVID-19 Resilience and Risk Reduction Intervention in Rural Populations of Western India: Retrospective Evaluation.JMIR public health and surveillance · 2024Article
- Vaccination strategies impact the probability of outbreak extinction: A case study of COVID-19 transmission.Heliyon · 2024Article
- Association between Gross National Income per capita and COVID-19 vaccination coverage: a global ecological study.BMC public health · 2023Article
- Acceptance of COVID-19 vaccine booster dose among the people of Bangladesh: A cross-sectional study.Heliyon · 2023Article
- Fair-split distribution of multi-dose vaccines with prioritized age groups and dynamic demand: The case study of COVID-19.European journal of operational research · 2023Article
- An update on vaccine status and the role of nanomedicine against SARS-CoV-2: A narrative review.Health science reports · 2023Article
- Spreading processes with mutations over multilayer networks.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Examining the Impact of Key Factors on COVID-19 Vaccination Coverage in India: A PLS-SEM Approach.Vaccines · 2023Article
- Review
- Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unprecedented toll of severe acute respiratory syndrome coronavirus 2, the virus responsible for coronavirus 2019 disease (COVID-19), jumpstarted the race towards the development and distribution of effective treatment and prevention options. With an urgent need to slow viral transmission, lessen disease severity, and reduce mortality, biopharmaceutical companies rapidly began investigating potential COVID-19 vaccinations. While typical vaccine development can take upwards of 10-15 years, COVID-19 vaccines were developed in less than a year after the identification of COVID-19. To accomplish this feat, clinical development, manufacturing scale-up and distribution are occurring in parallel for the four COVID-19 vaccine front-runners. This remarkable opportunity will forever change the drug development process and would not be possible without tremendous dedication from the public and private sectors, researchers, and clinical trial volunteers. However, many challenges still lie ahead. Comprehensive plans for equitable vaccine education, distribution, administration and post-marketing surveillance must be implemented successfully to overcome vaccine hesitancy, supply-chain obstacles and healthcare provider shortages in an already overburdened healthcare system. We are moving forward at a remarkable pace but worldwide immunity through vaccination will take time to achieve. Thus, current prevention efforts of masking, hand hygiene and social distancing must remain in effect for the foreseeable future. We must remain diligent and not fatigue in our efforts. Ending the COVID-19 pandemic cannot rest on the promise of vaccination alone - it will require a continued, robust and multi-faceted approach to disease treatment and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.